At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 21.18×, higher than 95% of its Biotechnology peers (median 5.6×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.92BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
76.81%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
1.92BUSDvs all stocks (USD)
Enterprise Value
1.57BUSDvs all stocks (USD)
Forward P/E
-15.68xvs Biotechnology peers
Price to Book (MRQ)
8.30xvs Biotechnology peers
Enterprise to EBITDA
-44.62xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.05%vs Biotechnology peers
Return on Equity (TTM)
-46.63%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-61.70MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-36.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.45MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-38.60MUSDvs all stocks (USD)
Pre-tax Income
-41.72MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-41.72MUSDFY2025 · Dec 31, 2025EBIT
-35.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-35.28MUSDFY2025 · Dec 31, 2025Research & Development
22.84MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.76MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.59MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.82MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.71USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.71USDFY2025 · Dec 31, 2025Basic Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.72MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-25.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
57.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.72MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.49MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.42MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.42MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.40MSharesUpdated Oct 28, 2026Float Shares
10.70MSharesUpdated Oct 28, 2026Shares Short
2.52MSharesUpdated Oct 28, 2026Short Ratio
11.77daysvs all stocks
Short % of Shares Outstanding
19.82%vs all stocks
% Held by Insiders
11.21%vs all stocks
% Held by Institutions
103.88%vs all stocks
Total Cash (MRQ)
250.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
17.39USDUpdated Oct 28, 2026Total Debt (MRQ)
22.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1044xvs Biotechnology peers
Current Ratio (MRQ)
21.18xvs Biotechnology peers
Book Value per Share (MRQ)
15.06USDUpdated Oct 28, 2026Total Assets
59.56MUSDvs all stocks (USD)
Total Current Assets
58.99MUSDFY2025 · Dec 31, 2025Total Liabilities
31.58MUSDFY2025 · Dec 31, 2025Total Non-current Assets
572.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.23MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
57.98MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
4.59MUSDFY2025 · Dec 31, 2025Short-term Debt
202.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.90MUSDFY2025 · Dec 31, 2025Long-term Debt
431.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
17.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
12.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-135.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
27.98MUSDvs all stocks (USD)
52-Week Low
71.55USDUpdated Oct 28, 202652-Week High
161.38USDUpdated Oct 28, 202652-Week Change
76.81%vs all stocks
50-Day MA
142.43USDUpdated Oct 28, 2026200-Day MA
125.90USDUpdated Oct 28, 2026Avg 10-Day Volume
228.36KSharesUpdated Oct 28, 2026Avg 30-Day Volume
233.97KSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-4.85USDUpdated Oct 28, 2026Other Income / Expense
115.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 21.18×, higher than 95% of its Biotechnology peers (median 5.6×)Significant
Current ratio: 21.18Industry median: 5.60Industry P95: 20.85Peers compared: 245
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Market cap is $1.92B, above the global median of $1.14BNotable
Market cap (USD): 1,915,021,374Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule